Low-dose interleukin-2 induced remission of the main symptoms of hepatitis C virus–related vasculitis in 8 of 10 patients participating in a phase I/phase II clinical trial, according to results reported in the Dec. 1 issue of the New England Journal of Medicine.
The remission of purpura, arthralgia, and nephropathy was accompanied by a 420% increase in the potently suppressive regulatory T cells known as Tregs, which are abnormally decreased in patients who have mixed cryoglobulinemic vasculitis induced by chronic infection with hepatitis C virus, said Dr. David Saadoun of the Université Pierre et Marie Curie, Paris, and his associates (N. Engl. J. Med. 2011;365:2067-77).
0 comments:
Post a Comment